Switching from biosimilar adalimumab to originator adalimumab and vice versa as an alternative to target switch in patients with hidradenitis suppurativa: a single center experience

被引：0
|
作者：
Roldan, Fernando Alfageme [1 ]
Cembrero, Hirune [1 ]
Salguero, Irene [1 ]
Martinez, Constanza [1 ]
Roustan, Gaston [1 ]
机构：
[1] Hosp Univ Puerta de Hierro Majadahonda, Dermatol, Madrid, Spain
来源：
EXPERIMENTAL DERMATOLOGY | 2021年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P167
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [31] MAINTENANCE OF CLINICAL REMISSION WITH SB5 BIOSIMILAR AFTER SWITCH FROM ADALIMUMAB ORIGINATOR: REAL-LIFE EXPERIENCE OF A TERTIARY REFERRAL CENTER
    Dragoni, G.
    Pieraccini, A.
    Bagnoli, S.
    Caini, S.
    Macri, G.
    Rogai, F.
    Milani, S.
    Galli, A.
    Milla, M.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S120 - S120
  • [32] Evaluation of trough level and disease activity after switch from adalimumab originator to biosimilar in patients with Inflammatory Bowel Disease
    Deprez, N.
    De Somer, T.
    Baert, D.
    Deceuninck, M.
    Huys, I.
    Mattens, V.
    Sterckx, A.
    Vanden Branden, S.
    Vanderstraeten, E.
    Vandervoort, J.
    Vanheddegem, N.
    Dewint, P.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S314 - S315
  • [33] Evaluation of the nocebo effect after switching from etanercept or adalimumab originator to a biosimilar: a retrospective study of patients with inflammatory rheumatism
    Hagege, O.
    Brevet, P.
    Gerard, B.
    Duhamel, E.
    Mihailescu, S. -d.
    Alcaix, D.
    Weber, A. -J
    Marcelli, C.
    Grosjean, J.
    Varin, R.
    Lequerre, T.
    Vittecoq, O.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2025, 43 (01) : 87 - 95
  • [34] SWITCHING FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR SB5(IMRALDI) - IBD SERVICE ASSESSMENT AND NEEDS
    Koumoutsos, Ioannis
    Cowperthwaite, Susan
    Glover, Sharon
    Sheil, Chloe
    Vakeeswarasarma, Vithushan
    Strickland, Christopher
    GUT, 2021, 70 : A105 - A105
  • [35] EFFECTIVENESS AND SAFETY OF ABP501, AN ADALIMUMAB BIOSIMILAR, IN NAIVE PATIENTS WITH IBD AND IN THOSE UNDERGOING SWITCHING FROM ADALIMUMAB ORIGINATOR: A MULTICENTRIC NORTH ITALIAN STUDY.
    Barberio, Brigida
    Zingone, Fabiana
    Melatti, Piera
    Ferronato, Antonio
    Buda, Andrea
    Bertani, Lorenzo
    Bodini, Giorgia
    Gubbiotti, Alessandro
    Massimi, Davide
    Lorenzon, Greta
    Savarino, Edoardo
    GASTROENTEROLOGY, 2020, 158 (06) : S410 - S410
  • [36] Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa. Our clinical experience
    Moyano-Almagro, Blanca
    Contreras-Steyls, Marisol
    Mendez-Abad, Cristina
    Collado-Minguillon, Andres
    Antonio Jaramillo, Juan
    Delgado-Ceballos, Jaime
    Russo-DelaTorre, Francisco
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB208 - AB208
  • [37] Tildrakizumab for the treatment of hidradenitis suppurativa in patients refractory to adalimumab-An Australian Dermatology Department experience
    Koszegi, Ben
    Cowan, Timothy
    Wilson, Anna
    Stone, Corey
    Murrell, Dedee
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 73 - 74
  • [38] Assessing the Role of Adalimumab in Treating Hidradenitis Suppurativa: Findings from a Retrospective Study at a Reference Center
    Sakaityte, Austeja
    Cesnaviciute, Inga
    Raudonis, Tadas
    CLINICS AND PRACTICE, 2024, 14 (05) : 1696 - 1706
  • [39] Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience
    Koszegi, Ben
    Wilson, Anna
    Stone, Corey
    Satge, Fanny
    Cowan, Timothy L.
    Murrell, Dedee F.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (11) : 1266 - 1269
  • [40] Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto
    Pham, Catherine
    Bitar, Deana
    Niu, Fang
    Le, Kim Ngoc
    Hui, Rita Lai-Han
    Delate, Thomas
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025,
12345